Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies

Business Wire March 7, 2019

Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women

Business Wire March 6, 2019

Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance

Business Wire March 6, 2019

Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection

Business Wire March 6, 2019

Gilead Announces Senior Management Change

Business Wire March 5, 2019

Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12

Business Wire March 5, 2019

Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV

Business Wire February 26, 2019

Gilead Receives Approval in Canada for YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy for Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy

Canada NewsWire February 19, 2019

The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Benzinga.com  February 15, 2019

26 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  February 12, 2019

The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares

Benzinga.com  February 12, 2019

A Peek Into The Markets: US Stock Futures Point To Higher Wall Street Open

Benzinga.com  February 12, 2019

7 Stocks Moving In Monday's After-Hours Session

Benzinga.com  February 11, 2019

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Business Wire February 11, 2019

For Sale: Performance Stocks, Slightly Worn

Benzinga.com  February 7, 2019

January's Market Bounce Resulted In Some Unexpected Retail Trading Trends

Benzinga.com  February 5, 2019

Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4

Benzinga.com  February 5, 2019

Investor Movement Index January Summary

Benzinga.com  February 5, 2019

The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Benzinga.com  February 5, 2019

Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend

Business Wire February 4, 2019